HRP20181447T1 - Pripravci glp-1 peptida i njihova priprava - Google Patents

Pripravci glp-1 peptida i njihova priprava

Info

Publication number
HRP20181447T1
HRP20181447T1 HRP20181447TT HRP20181447T HRP20181447T1 HR P20181447 T1 HRP20181447 T1 HR P20181447T1 HR P20181447T T HRP20181447T T HR P20181447TT HR P20181447 T HRP20181447 T HR P20181447T HR P20181447 T1 HRP20181447 T1 HR P20181447T1
Authority
HR
Croatia
Prior art keywords
glp
peptides
compositions
preparation
Prior art date
Application number
HRP20181447TT
Other languages
English (en)
Inventor
Thomas Vilhelmsen
Helle Eliasen
Tue Hansen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181447(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20181447T1 publication Critical patent/HRP20181447T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
HRP20181447TT 2012-03-22 2018-09-11 Pripravci glp-1 peptida i njihova priprava HRP20181447T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12160743 2012-03-22
US201361748840P 2013-01-04 2013-01-04
EP13153459 2013-01-31
EP13709231.8A EP2827885B1 (en) 2012-03-22 2013-03-15 Compositions of glp-1 peptides and preparation thereof
PCT/EP2013/055362 WO2013139694A1 (en) 2012-03-22 2013-03-15 Compositions of glp-1 peptides and preparation thereof

Publications (1)

Publication Number Publication Date
HRP20181447T1 true HRP20181447T1 (hr) 2018-11-02

Family

ID=49221868

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20231060TT HRP20231060T1 (hr) 2012-03-22 2013-03-15 Pripravci peptida glp-1 i njihova priprava
HRP20181447TT HRP20181447T1 (hr) 2012-03-22 2018-09-11 Pripravci glp-1 peptida i njihova priprava

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20231060TT HRP20231060T1 (hr) 2012-03-22 2013-03-15 Pripravci peptida glp-1 i njihova priprava

Country Status (21)

Country Link
US (5) US10933120B2 (hr)
EP (3) EP3488857B9 (hr)
JP (1) JP6001158B2 (hr)
KR (1) KR102072202B1 (hr)
CN (2) CN104203266B (hr)
AU (2) AU2013234496B2 (hr)
BR (1) BR112014023374B1 (hr)
CA (1) CA2868188A1 (hr)
DK (1) DK2827885T3 (hr)
ES (2) ES2952874T3 (hr)
HR (2) HRP20231060T1 (hr)
HU (2) HUE039406T2 (hr)
LT (1) LT2827885T (hr)
MX (1) MX353067B (hr)
MY (1) MY171146A (hr)
PL (2) PL2827885T3 (hr)
RS (2) RS57727B1 (hr)
RU (1) RU2641198C3 (hr)
SI (1) SI2827885T1 (hr)
WO (1) WO2013139694A1 (hr)
ZA (1) ZA201406250B (hr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CN106117344B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
KR102266299B1 (ko) * 2012-03-22 2021-06-18 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HRP20231613T1 (hr) 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
BR112015026325A2 (pt) * 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
JP7053480B2 (ja) 2016-03-03 2022-04-12 ノヴォ ノルディスク アー／エス Ｇｌｐ－１誘導体及びその使用
CN108606957A (zh) * 2016-12-13 2018-10-02 南京星银药业集团有限公司 一种含索马鲁肽的口服缓释制剂及其制备方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2019173571A1 (en) * 2018-03-09 2019-09-12 Northwestern University Insulin-loaded metal-organic frameworks
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN111265654B (zh) * 2018-12-05 2023-05-16 江苏恒瑞医药股份有限公司 Glp-1类似物的药物组合物及其制备方法
MA54510A (fr) 2018-12-21 2022-03-30 Novo Nordisk As Procédé de séchage par pulvérisation de peptide glp-1
JP2022520011A (ja) * 2019-01-24 2022-03-28 ノヴォ ノルディスク アー／エス ローラコンパクタおよびローラコンパクタを使用する乾式造粒の方法
CN113631251A (zh) * 2019-03-15 2021-11-09 诺和诺德股份有限公司 Glp-1肽的喷雾干燥工艺
BR112022000529A2 (pt) 2019-08-07 2022-03-03 Novo Nordisk As Composição farmacêutica
WO2021023817A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021089761A1 (en) 2019-11-07 2021-05-14 Novo Nordisk A/S Solid compositions comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US20220395559A1 (en) 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN115461044A (zh) 2020-04-29 2022-12-09 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
TW202227474A (zh) 2020-12-18 2022-07-16 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ－１及澱粉素受體之共促效劑
EP4333814A1 (en) * 2021-05-07 2024-03-13 Eli Lilly and Company Erodible tablet
US20230000764A1 (en) * 2021-06-11 2023-01-05 Boa Nutrition, Inc. Pressurized nutritional supplement delivery
EP4360645A1 (en) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical composition containing glp-1 compound
CN117979958A (zh) 2021-07-15 2024-05-03 诺和诺德股份有限公司 包含n-(8-(2-羟基苯甲酰基)氨基)辛酸盐的片剂
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
TW202333774A (zh) * 2021-12-01 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 Glp-1和gip受體雙重激動劑的醫藥組成物及其用途
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU609031B2 (en) 1986-03-12 1991-04-26 American Cyanamid Company Macrolide compounds
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0803255A4 (en) 1994-06-03 1999-06-30 Tsumura & Co DRUG
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2237790T3 (es) 1996-11-12 2005-08-01 Novo Nordisk A/S Uso de peptidos glp-1.
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
ES2188264T3 (es) 1998-06-08 2003-06-16 Schering Corp Antagonistas del receptor del neuropeptido y5.
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
WO2000007617A1 (en) 1998-07-31 2000-02-17 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
NZ527241A (en) 1998-12-07 2004-12-24 Sod Conseils Rech Applic Analogues of GLP-1
CA2361716C (en) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ATE386508T1 (de) 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
AU775063C (en) 1999-04-30 2005-05-12 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
CA2466863A1 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2003063838A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
DE60327771D1 (de) 2002-07-04 2009-07-09 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
PL1605897T3 (pl) 2003-03-19 2012-12-31 Lilly Co Eli Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
BRPI0411165A (pt) 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
CN1809377B (zh) 2003-07-11 2010-08-04 诺瓦提斯公司 包含微粉化形式的传送剂的口服给药药物组合物
JP2007501811A (ja) 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
RU2006120079A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Производные глюкагоноподобного пептида-1 (glp-1)
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
WO2005089786A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
JP2007531713A (ja) 2004-03-17 2007-11-08 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ２選択性レセプターアゴニスト
WO2005089790A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
AU2005240206B2 (en) 2004-05-06 2011-04-07 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
CN102040537A (zh) 2004-05-06 2011-05-04 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
CA2565188C (en) * 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US20090111730A1 (en) 2004-07-08 2009-04-30 Novo Nordisk A/S Polypeptide protracting tags
US9399054B2 (en) 2004-07-12 2016-07-26 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
CA2599723A1 (en) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
US20090062192A1 (en) 2005-03-18 2009-03-05 Novo Nordisk A/S Dimeric Peptide Agonists of the Glp-1 Receptor
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
US20080260818A1 (en) 2005-03-28 2008-10-23 Dexcel Pharma Technologies Ltd. Controlled Absorption of Statins in the Intestine
CN101282991A (zh) 2005-05-26 2008-10-08 布里斯托尔-迈尔斯斯奎布公司 N-端修饰的胰高血糖素样肽-1受体调节剂
CA2614619A1 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
WO2007011958A2 (en) 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
BRPI0613984A2 (pt) 2005-07-18 2011-03-01 Novo Nordisk As peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
US20090239796A1 (en) 2005-08-19 2009-09-24 Amylin Pharmaceuticals, Inc. Methods for treating diabetes and reducing body weight
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
BRPI0520566A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y2 seletivos para intervenções terapêuticas
US8022035B2 (en) 2005-09-21 2011-09-20 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
CA2626933C (en) 2005-11-17 2015-12-29 Novartis Ag Pharmaceutical composition
AU2006324076A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2007067964A2 (en) 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
JP2009519296A (ja) 2005-12-14 2009-05-14 ノボ・ノルデイスク・エー／エス ポリペプチド延長タグ
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
US20090186817A1 (en) 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
KR101441444B1 (ko) 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
EP2040718B1 (en) 2006-06-28 2017-12-27 Emisphere Technologies, Inc. Gallium nitrate formulations
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US10875826B2 (en) 2006-09-07 2020-12-29 Emisphere Technologies, Inc. Process for the manufacture of SNAC (salcaprozate sodium)
PE20080840A1 (es) 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
AR062925A1 (es) 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
WO2008070547A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
MX2009009243A (es) 2007-03-02 2009-09-08 Novartis Ag Administracion oral de una calcitonina.
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2171080A4 (en) 2007-06-12 2010-10-27 Glaxosmithkline Llc METHODS OF PROTEIN DETECTION IN PLASMA
US8093689B2 (en) * 2007-07-02 2012-01-10 Infineon Technologies Ag Attachment member for semiconductor sensor device
CN101970475A (zh) 2007-07-09 2011-02-09 帝国改革有限公司 人类胰多肽(hpp)类似物及其对摄食行为的作用
AU2008296444A1 (en) 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN101842386A (zh) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
CA2698852A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
DK2215047T3 (da) 2007-11-02 2014-02-03 Emisphere Tech Inc Fremgangsmåde til behandling af vitamin b12-mangel
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
AU2009248041B2 (en) 2008-05-16 2013-10-03 Novo Nordisk A/S Long-acting Y2 and/or Y4 receptor agonists
AU2009283821B2 (en) * 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
PT2386203E (pt) 2008-10-15 2014-02-17 Bayer Cropscience Ag Utilização de ditiina-tetracarboximidas para combater fungos fitopatogénicos
BRPI0921230A2 (pt) 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
BRPI1008039A2 (pt) 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
US20130040877A1 (en) 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2488195A2 (en) 2009-10-13 2012-08-22 F. Hoffmann-La Roche AG Neuropeptide-2 receptor (y-2r) agonists
CN102905722A (zh) 2009-11-13 2013-01-30 诺沃—诺迪斯克有限公司 长效y2受体激动剂
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
JP2013514976A (ja) 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
CN106117344B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
HRP20231613T1 (hr) 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
MX366405B (es) 2012-07-01 2019-07-08 Novo Nordisk As Uso de peptidos glp-1 de accion prolongada.
RU2015144632A (ru) 2013-05-02 2017-06-07 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
TWI661835B (zh) 2013-11-15 2019-06-11 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
EP3256113A4 (en) 2015-02-09 2018-11-14 Entera Bio Ltd. Treatment of hypoparathyroidism
RU2726777C2 (ru) 2015-06-12 2020-07-15 Ново Нордиск А/С Селективные соединения пептида yy и их применения
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Also Published As

Publication number Publication date
CN107812181B (zh) 2022-06-17
CN104203266A (zh) 2014-12-10
CA2868188A1 (en) 2013-09-26
BR112014023374A2 (pt) 2017-07-11
PL2827885T3 (pl) 2019-01-31
EP2827885B1 (en) 2018-08-15
EP3488857B1 (en) 2023-06-07
EP4324475A1 (en) 2024-02-21
CN107812181A (zh) 2018-03-20
RU2641198C3 (ru) 2021-12-10
WO2013139694A1 (en) 2013-09-26
JP6001158B2 (ja) 2016-10-05
US20220362346A1 (en) 2022-11-17
RU2641198C2 (ru) 2018-01-16
CN104203266B (zh) 2017-12-26
MX2014010685A (es) 2014-10-13
US11759502B2 (en) 2023-09-19
EP3488857A1 (en) 2019-05-29
ES2952874T3 (es) 2023-11-06
LT2827885T (lt) 2018-10-10
ES2690553T3 (es) 2018-11-21
KR102072202B1 (ko) 2020-01-31
RU2014141700A (ru) 2016-05-20
PL3488857T3 (pl) 2023-12-11
US20150072926A1 (en) 2015-03-12
US20210162012A1 (en) 2021-06-03
HRP20231060T1 (hr) 2023-12-22
SI2827885T1 (sl) 2018-10-30
JP2015512374A (ja) 2015-04-27
US11759503B2 (en) 2023-09-19
AU2013234496B2 (en) 2017-07-27
ZA201406250B (en) 2022-05-25
US20220331404A1 (en) 2022-10-20
AU2017251814A1 (en) 2017-11-16
AU2013234496A1 (en) 2014-09-11
RS57727B1 (sr) 2018-12-31
AU2017251814B2 (en) 2019-06-13
US11759501B2 (en) 2023-09-19
EP3488857C0 (en) 2023-06-07
EP2827885A1 (en) 2015-01-28
KR20140138873A (ko) 2014-12-04
HUE062740T2 (hu) 2023-12-28
DK2827885T3 (en) 2018-10-08
BR112014023374B1 (pt) 2021-09-21
BR112014023374A8 (pt) 2018-01-16
US20240016897A1 (en) 2024-01-18
MY171146A (en) 2019-09-27
RS64460B1 (sr) 2023-09-29
EP3488857B9 (en) 2023-10-04
MX353067B (es) 2017-12-19
HUE039406T2 (hu) 2018-12-28
US10933120B2 (en) 2021-03-02

Similar Documents

Publication Publication Date Title
HRP20181447T1 (hr) Pripravci glp-1 peptida i njihova priprava
HK1207001A1 (en) Immunostimulatory compositions and methods of use thereof
EP2906212A4 (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS
HRP20180633T1 (hr) Postupak za pripremu i provedbu smjese goriva
HK1215793A1 (zh) 的凍乾製劑
HK1203161A1 (en) Peptides and methods of using same
EP2897639A4 (en) IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
HK1203149A1 (en) Novel dosage form and formulation of abediterol
EP2775831A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
HK1213151A1 (zh) 葉黃素組合物及使用方法
EP2852370A4 (en) FLASH-CONTAINING COMPOSITIONS AND METHODS OF USE
EP2741762A4 (en) NATRIURETIC PEPTIDE COMPOSITIONS AND PREPARATION METHODS
IL234228B (en) Compositions of glp-1 peptides and preparation thereof
HK1212998A1 (zh) 組合物及其使用方法
GB201219884D0 (en) New composition and preparation thereof
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN